The global microneedle drug delivery systems market size was estimated at USD 6.11 billion in 2024 and is projected to grow at a CAGR of 7.7% from 2025 to 2030. According to the World Health Organization, 31% of adults worldwide, approximately 1.8 billion, failed to meet physical activity recommendations in previous years, increasing disease risk. The slowdown in healthy life expectancy improvement reflected the burden of noncommunicable diseases. In another study towards the National Diabetes Statistics Report revealed that the U.S. witnessed 34.2 million cases of diabetes in 2024, highlighting the need for innovative solutions to address these growing health concerns and improve patient outcomes.
Continuous innovation has led to the development of biodegradable and dissolvable microneedles, as well as their integration with wearable technology. Such advancements enable greater control over drug delivery kinetics and improve efficacy, making microneedle drug delivery systems (MNDDS) particularly appealing to pharmaceutical manufacturers. Moreover, the rising demand for biologics, which require efficient delivery mechanisms, has positioned microneedles as an optimal choice for therapeutic applications.
The demand for minimally invasive drug delivery methods has driven market growth further. MNDDS offer a virtually painless alternative to traditional hypodermic injections, significantly enhancing patient compliance by simplifying the drug administration process. As patients increasingly prefer self-administration options, these systems reduce the necessity for frequent hospital visits, thereby lowering overall healthcare costs.
Moreover, the COVID-19 pandemic has catalyzed interest in microneedle technology for vaccine delivery, as it allows for administration without healthcare professionals, minimizing exposure risks in clinical settings. The pandemic has ignited funding and research into microneedle solutions, instigating a long-term shift in drug delivery paradigms. Regions such as Asia Pacific and Latin America are expected to witness significant industry growth, aided by government initiatives such as the FDA’s approval of microneedle devices for clinical trials and growing investments in healthcare infrastructure.
Hollow microneedles dominated the market and accounted for a share of 26.7% in 2024. These micron-sized devices function as micro-syringes, allowing for the delivery of various therapies, including vaccines, insulin, and peptides, which improves patient compliance. They are particularly suitable for managing chronic diseases requiring multiple doses, as they reduce injection pain and enhance the patient experience. The International Diabetes Federation reported that the number of adults with diabetes has surpassed 800 million worldwide, emphasizing the growing need for innovative drug delivery solutions.
Dissolving microneedles are expected to grow at the fastest CAGR of 5.6% over the forecast period. As the dissolving microneedle is a less painful method of delivering active ingredients than the syringe, it only requires one step, as the microneedle needs not to be removed after insertion. For patients, who would otherwise require frequent injections, this could potentially improve their quality of life. Furthermore, there is a rising interest in dissolving microneedles constructed of biodegradable materials, as they enable drug administration without leaving sharp, bio-contaminated, and non-degradable waste, as the microneedles dissolve into the skin after insertion. All these factors are expected to have a positive impact on market growth.
Metal led the market with a revenue share of 28.1% in 2024. Stainless steel and titanium are the primary metals used in microneedle manufacturing, noted for their mechanical strength and biocompatibility. Other metals such as palladium, nickel, and palladium-cobalt alloys are also utilized. These materials are favored for their durability and versatility, as they can be shaped into hollow, coated, or solid-state microneedles. Advances in additive manufacturing have enabled cost-effective production, while metallic microneedles improve skin permeability, enhancing drug bioavailability and therapeutic efficiency compared to non-invasive patches.
Polymer is expected to register significant growth over the forecast period, owing to their biocompatibility, biodegradability, and non-toxicity. They are easily produced at scale and customizable for various mechanical properties. Polymeric microneedles also enhance drug bioavailability and control release while minimizing pain by delivering larger molecules without disturbing skin nerve endings, utilizing design strategies such as 3D printing with biodegradable materials such as polylactic acid (PLA).
Applications in drug delivery held the largest market share of 34.3% in 2024. Insulin, a peptide hormone, is increasingly delivered through MNDDS due to the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions. MNDDS offer painless administration by bypassing nerve fibers, improved drug delivery with enhanced bioavailability, and versatile applications for various therapeutics, including vaccines. Moreover, they promote patient compliance, reduce infection risk, and generate less hazardous waste compared to traditional needles.
Vaccine delivery is projected to grow at the fastest CAGR of 8.7% over the forecast period, aided by their painless and targeted approach. MNDDS offer versatility, administering various vaccine types, eliminate the need for cold storage, and facilitate self-administration. They can also stimulate strong immune responses with lower doses, provide long-lasting immunity, reduce needle-stick injuries and biohazardous waste, and simplify logistics and costs.
North America microneedle drug delivery systems market dominated the global market with a revenue share of 43.1% in 2024. Driven by high healthcare spending, the rising prevalence of chronic diseases, and growing awareness of advanced drug delivery systems, North America is expected to sustain its market dominance. Partnerships, such as Cynosure’s collaboration with LaserAway, aim to enhance the availability of innovative MNDDS technologies across the region. In addition, the regulatory environment is favorable to the development and commercialization of MNDDS. Both the U.S. FDA and Health Canada are supportive of the development of microneedle technology, which has led to increased investment and innovation in the market.
The microneedle drug delivery systems market in U.S. dominated the North America market with a revenue share of 81.7% in 2024, supported by its advanced healthcare infrastructure, strong focus on technological innovation, and robust research infrastructure. The rise in incidence of chronic diseases in the country has accelerated adoption. For instance, according to a CDC study conducted between August 2021 and August 2023, approximately 15.8% of the population was affected by diabetes. Key factors include significant investments in R&D, a favorable regulatory environment, increasing hospital adoption, and expanding applications, and substantial investments in drug delivery technologies.
Europe microneedle drug delivery systems market held substantial market share in 2024. Factors fueling market growth include increasing research activities, healthcare expenditure, and awareness of advanced technologies. The manufacturing landscape is evolving, with investments in advanced production capabilities and automated processes, ensuring consistent product performance. The presence of major pharmaceutical companies further fosters innovation in microneedle technology throughout the region.
The microneedle drug delivery systems market in Germany is expected to grow rapidly in the forecast period, driven by robust research and development capabilities, high healthcare spending, and increasing chronic disease prevalence. The manufacturing landscape is evolving as companies invest in advanced production capabilities, integrating automated processes and sophisticated micro-engineering.
Asia Pacific microneedle drug delivery systems market is expected to register the fastest CAGR of 9.0% in the forecast period. The market for MNDDS is growing in China, Japan, and India due to increasing healthcare expenditure, a large patient population, and heightened awareness of advanced drug delivery technologies. Government initiatives, such as India’s 2021 Digital Health Mission, foster innovation, while strategic partnerships between technology providers and pharmaceutical companies enhance R&D activities, contributing to a robust pipeline of next-generation delivery solutions.
The microneedle drug delivery systems market in China is expected to grow at the fastest CAGR of 9.5% over the forecast period, driven by a large patient population, increasing healthcare expenditure, and the adoption of advanced medical technologies. Strategic partnerships and investments are accelerating industry growth and fostering collaboration between technology providers and pharmaceutical companies.
Some key companies operating in the market include Raphas Co., Ltd.; Novartis AG; BD; and B. Braun SE; among others. The market is highly competitive, with large number of manufacturers accounting for a majority of market share. Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by the market participants to maintain and grow their global reach.
Raphas, a South Korean technology company, specializes in dissolvable microneedle technology for skincare, medical devices, and pharmaceuticals. Their Droplet-born Air Blowing (DAB) technology enables cost-effective mass production of customizable microneedle patches, alongside securing multiple patents and certifications for innovation.
B. Braun offers products such as micro needle holders, including the Dia Dust and DUROGRIP lines, designed for precise handling during surgeries. Moreover, their MICRO PIN is a non-vented, single-use dispensing pin, ensuring efficient withdrawal and injection of medications from rubber-stoppered vials.
The following are the leading companies in the microneedle drug delivery systems (MNDDS) market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Microneedle Drug Delivery Systems Market
In February 2025, BD, a global medical technology company based in New Jersey, announced its plan to separate its Biosciences and Diagnostic Solutions business to enhance focus, drive growth, and unlock value for shareholders through tailored investment and market valuation optimization.
In October 2024, Ya-Man, a Japanese beauty device company, launched a new skin care series featuring 24K gold-coated microneedles, aimed at supporting overall skin health and addressing signs of aging in the Asian market
Report Attribute |
Details |
Market size value in 2025 |
USD 6.53 billion |
Revenue forecast in 2030 |
USD 9.46 billion |
Growth rate |
CAGR of 7.7% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Type, material, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait |
Key companies profiled |
Raphas Co., Ltd.; Novartis AG; BD; B. Braun SE; NanoPass; Terumo Corporation; Smiths Group plc; Cardinal Health; 3M |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global microneedle drug delivery systems market report based on type, material, application, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Hollow
Solid
Coated
Dissolving
Others
Material Outlook (Revenue, USD Million, 2018 - 2030)
Metal
Silicon
Polymer
Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
Drug Delivery
Vaccine Delivery
Pain Management
Cancer Therapy
Dermatology
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."